Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Consolidated Net Income (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Consolidated Net Income for 2 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Consolidated Net Income rose 195.92% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$11.9 million, a 334.38% decrease, with the full-year FY2025 number at -$6.6 million, up 51.41% from a year prior.
  • Consolidated Net Income was $1.9 million for Q4 2025 at Neuphoria Therapeutics, up from -$9.9 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $11.3 million in Q1 2025 to a low of -$15.2 million in Q2 2025.